Habib Jabagi

Dr. Habib Jabagi

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
RHRenée Hessian
Renée Hessian
HJHabib Jabagi
Habib Jabagi
JNJanet M.C. Ngu
Janet M.C. Ngu
FRFraser D. Rubens
Fraser D. Rubens

21 March 2022 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
MSMichel Pompeu B.O. Sá
Michel Pompeu B.O. Sá
HJHabib Jabagi
Habib Jabagi
ADAleksander Dokollari
Aleksander Dokollari
AAAhmed K. Awad
Ahmed K. Awad
Jef Van den EyndeJef Van den Eynde
Jef Van den Eynde
BRBasel Ramlawi
Basel Ramlawi

25 April 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HJHabib Jabagi
Habib Jabagi
LMLisa M. Mielniczuk
Lisa M. Mielniczuk
PLPeter P. Liu
Peter P. Liu
MRMarc Ruel
Marc Ruel
LSLouise Sun
Louise Sun
Right ventricular failure (RVF) is a major risk factor for end organ morbidity and mortality following cardiac surgery. Perioperative RVF is difficult to predict and detect, and to date, no convenient, accurate, or reproducible measure of right ventricular (RV) function is available. Few studies have examined the use of biomarkers in RVF, and even fewer have examined their utility in the perioperative setting of patients undergoing cardiac surgery. Of the available classes of biomarkers, this review focuses on biomarkers of (1) inflammation and (2) myocyte injury/stress, due to their superior potential in perioperative RV assessment, including Galectin 3, ST2/sST2, CRP, cTN/hs-cTn, and BNP/NT-proBNP. This review was performed to help highlight the importance of perioperative RV function in patients undergoing cardiac surgery, to review the current modalities of RV assessment, and to provide a review of RV specific biomarkers and their potential utilization in the clinical and perioperative setting in cardiac surgery. Based on current evidence, we suggest the potential utility of ST2, sST2, Gal-3, CRP, hs-cTn, and NT-proBNP in predicting and detecting RVF in cardiac surgery patients, as they encompass the multifaceted nature of perioperative RVF and warrant further investigation to establish their clinical utility.

9 December 2019 in Trials
Verified
Journal Article
Open access
PDF file
HJHabib Jabagi
Habib Jabagi
GWGeorge Wells
George Wells
MBMunir Boodhwani
Munir Boodhwani
Background: Aortic arch surgery remains the only viable life-saving treatment for aortic arch disease. However, the necessity for cessation of systemic blood flow with hypothermic cardiac arrest carries substantial risk of morbidity and mortality, including poor neurological outcomes and kidney failure. While uncontrolled studies have suggested the safety of operating at warmer temperatures, significant variables remain un-investigated, supporting the need for a randomized clinical trial (RCT) to produce evidence-based guidelines for perfusion strategies in aortic surgery. This study proposes a multi-center RCT in order to compare outcomes of warmer hypothermic strategies during aortic hemiarch surgery on a composite endpoint of neurologic and acute kidney injury (AKI).Methods/design: This is a prospective multi-center, single-blind two-arm RCT comparing mild (32 °C) versus moderate (26 °C) hypothermic cardiac arrest in patients (n = 282) undergoing hemiarch surgery with antegrade cerebral perfusion (ACP). The primary endpoint is a composite of neurological injury (incidence of transient ischemic attack and/or stroke) and Kidney Disease Improving Global Outcomes (KDIGO) stage 1 or higher AKI. Secondary outcomes include death, cardiopulmonary bypass time, bleeding, transfusion rates, prolonged mechanical ventilation, myocardial infarction, length of stay, and quality of life measures.Patients will undergo 1:1 block randomization to each treatment arm on day of surgery. Sequence of operation will be at the surgeon’s discretion with mandatory guidelines for temperature and ACP administration. Perioperative management will occur as per enrolling center standard of care. Neurocognitive function will be assessed for neurological injury using validated neurological screening tests: NIHSS, MOCA, BI, and MRS throughout patient follow-up. Diagnosis and classification of AKI will be based on rising creatinine values as per the KDIGO criteria. Study duration for each patient will be 60 ± 14 days.Discussion: It is hoped that performing hemiarch surgery using mild hypothermia (32 °C) and selective ACP will result in a 15% absolute risk reduction in the composite outcomes. The potential of this risk reduction will translate into improved patient outcomes, survival, and long-term financial savings to the health care system. In addition, the results of this trial will be used to create the first-ever guidelines for temperature management strategy during aortic surgery.Trial registration: This trial is registered on ClinicalTrials.gov with the registration numberNCT02860364. Registration date August 9th, 2016.

1 May 2022 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
HJHabib Jabagi
Habib Jabagi
VCVincent Chan
Vincent Chan
MRMarc Ruel
Marc Ruel
TMThierry G. Mesana
Thierry G. Mesana
MBMunir Boodhwani
Munir Boodhwani

22 January 2026 in Genetics in Medicine
Verified
Journal Article
Open access
HJHabib Jabagi
Habib Jabagi
RSRichard E. Shaw
Richard E. Shaw
AKAmy R. Kontorovich
Amy R. Kontorovich
VAVictor S. Alemany
Victor S. Alemany
CCCaitlin Ciallella
Caitlin Ciallella
JGJuan B. Grau
Juan B. Grau
Thoracic aortic aneurysms (TAA) are typically asymptomatic until rupture or dissection, with research indicating up to 20% may have a genetic basis. This study evaluates the prevalence of hereditary aortopathies and the utility of genetic testing in adults with TAA applying current ACC/AHA guidelines. We assessed 1323 consecutive adult patients presenting for TAA evaluation between July 2022 and April 2025 at a large aortic center, enrolling 426 patients who underwent guideline-driven genetic testing. Median (IQR) age was 57 (50-64) years, 22.8% were female, and 11.3% had bicuspid aortic valves. Mean aortic diameter was 4.6 ± 0.48 cm; 67.1% had TAA and 2.1% had dissections. Statistical analyses assessed the prevalence of genetic aortopathies and risk factors. Of the 426 patients, 2.6% had diagnostic tests identifying pathogenic variants, 68.3% tested negative, and 29.1% had variants of unknown significance (VUS). Diagnostic tests were significantly associated with younger age(P = .05) and root aneurysms(P < .001). No VUS associations were demonstrated. Gender and bicuspid aortic valves were not associated with diagnostic tests or VUS. TAA diagnosis < 60 years and familial history had the highest utility of the ACC/AHA recommendations but were not significant. Our findings suggest a lower prevalence of genotype-positive TAA than previously reported in all TAA patients; highlighting the need for more refined genetic testing criteria focusing on high-risk individuals. Further research is essential to better define genetic testing's role in TAA management.